Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Clinical trial NCT06365619 · RECRUITING
Trial details
- NCT number
- NCT06365619
- Sponsor
- University of Utah
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2027-08-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.